Clinical Trials
Sep 26, 2026 · 1 min read · 43,986 views
Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials
A
Aiden Brooks
Editorial · Sep 26, 2026
Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns on two life-threatening cases of allergic reaction following administration of the drug. The
← Previous
After years of hype, the first AI-designed drugs fall short in the clinic
Next →
Iambic releases next version of its Enchant model, signs deal with AbbVie
